Pulsetto has been recognized with a 2025 Global Recognition Award for converting medical-grade vagus nerve stimulation technology into a consumer device that addresses the global mental health crisis. CEO and co-founder Povilas Sabaliauskas lost his father to unexplained causes, while co-founder Vitalijus Majorovas watched his wife suffer from cluster headaches with no effective treatment, and their shared experiences drove them to create a device that targets stress through direct bilateral vagus nerve stimulation. The company has grown to serve 130,000 active users and achieved substantial revenue growth, reaching €10.9 million in the first half of 2025 alone while surpassing its entire 2024 performance of €10 million in just six months.

The award evaluation process employs the Rasch model to create linear measurement scales for precise comparisons across different excellence categories, and this methodology identified Pulsetto’s exceptional performance in innovation. The company scored at the highest level across six innovation criteria, including novelty and originality, market impact, technological advancement, addressing global challenges, adoption rate, and disruption of existing paradigms. This recognition reflects both the technical sophistication of the device and its demonstrated effectiveness in clinical settings, positioning Pulsetto as a leader in accessible neurotechnology solutions.

Technical Innovation and Market Disruption

Pulsetto FIT delivers bilateral vagus nerve stimulation through ergonomic hardware that adapts to different neck shapes, utilizing magnetically attached padding in three sizes. The device operates in four-minute sessions to activate the parasympathetic nervous system, shifting the body from a state of stress to a state of calm. Previous vagus nerve stimulation devices required handheld operation or employed indirect stimulation methods, which limited their practical application for managing daily stress and reduced user compliance over extended periods. The company positioned its technology as a hands-free wearable device for cervical vagus nerve stimulation, representing the only bilateral solution currently available on the consumer market.

The company’s approach addresses a documented crisis in mental health management where antidepressant use in Western countries has increased 66 percent over six years, while 40 percent of people turn to alcohol and 38 percent to smoking for stress relief. Pulsetto offers a non-pharmaceutical intervention that integrates firmware, app control, and hardware design into a wearable form factor. The device’s design converts clinical neurotechnology into an accessible consumer product that users can incorporate into their daily routines without medical supervision. The app offers five preset stimulation modes, including stress, anxiety, burnout, sleep, and pain relief, with nine different intensity levels that allow users to customize their experience based on individual needs and tolerance.

Clinical Validation and Global Expansion

Pulsetto completed clinical trials that demonstrated significant health improvements, and results showed depression symptoms decreased 56 percent on the PHQ-9 scale. Anxiety reduced by 45 percent on the GAD-7 assessment, and sleep quality improved by 41 percent according to PSQI measurements. The company reports that 86 percent of users experienced reduced anxiety after two weeks of regular use. After 15 sessions with the device, 64.5 percent of users experienced a reduction in anxiety and stress that provided long-term relief in everyday life. Research indicates that bilateral transcutaneous vagus nerve stimulation may alleviate physiological stress indicators and enhance self-reported symptoms related to depression, anxiety, and sleep disturbances through activation of the parasympathetic nervous system.

Stimulating the vagus nerve activates the parasympathetic nervous system, leading to a decrease in heart rate and an increase in heart rate variability within two to four weeks, while also reducing cortisol levels that are directly linked to stress states. Pulsetto has achieved a global reach across over 70 countries, with plans for retail launches in London and New York. The company’s expansion demonstrates the universal demand for accessible stress management technology. Second-quarter 2025 revenue reached €6.65 million, marking a 55.61 percent growth over the first quarter and validating the market’s appetite for non-invasive neurotechnology solutions that bridge clinical efficacy with consumer convenience.

Final Words

Pulsetto’s achievement represents a fundamental shift in how neurotechnology reaches consumers, as the company has converted a clinical intervention into a product that over 100,000 people use regularly, demonstrating that complex nervous system regulation can be made accessible through thoughtful design. The combination of clinical evidence, user adoption rates, and revenue growth validates the market need for non-pharmaceutical stress management tools that offer measurable physiological benefits without the side effects associated with traditional pharmaceutical interventions. The company’s trajectory illustrates how personal experiences with healthcare gaps can catalyze meaningful technological advancement when coupled with rigorous scientific validation and user-centered design principles.

Alex Sterling, spokesperson for Global Recognition Awards, noted the company’s impact while observing, saying that “Pulsetto has demonstrated rigorous clinical validation and that consumer product design and scientific integrity are not mutually exclusive concepts, and the company’s ability to scale a neurotechnology solution while maintaining scientific integrity sets a new standard for the wellness technology sector.” The work of Sabaliauskas and Majorovas positions vagus nerve stimulation as a practical intervention for stress-related health challenges affecting millions globally, and their success shows how founders can convert personal tragedy into innovation that serves a broader population struggling with the same physiological and psychological burdens. Pulsetto’s recognition through this award acknowledges both the technical merit of its bilateral cervical stimulation approach and the company’s success in making previously inaccessible medical technology available to everyday consumers who seek evidence-based alternatives to pharmaceutical stress management.